Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_assertion type Assertion NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_head.
- NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_assertion description "[Somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemias (AML) and secondary AML (sAML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_provenance.
- NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_assertion evidence source_evidence_literature NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_provenance.
- NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_assertion SIO_000772 21057493 NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_provenance.
- NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_assertion wasDerivedFrom befree-2016 NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_provenance.
- NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_assertion wasGeneratedBy ECO_0000203 NP850905.RAsjQujeImqHvlRCpYO96FlkmoL7rR3J4o9JiEgU_PpLw130_provenance.